在中度至重度牛皮患者中使用全身和生物疗法
Mie S Liljendahl1,2, Nikolai Loft1, Tri-Long Nguyen3
1Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Gentofte Hospitalsvej 15, 2900 Hellerup, University of Copenhagen, Denmark.
Clinical and experimental dermatology
|August 23, 2023
概括
近37.7%的丹麦中度至重度牛皮患者有资格接受全身治疗,但没有接受治疗. 对于那些接受传统的全身疗法的人来说,药物生存率随着时间的推移而显著下降.
科学领域:
- 皮肤病学 皮肤病学
- 公共卫生 公共卫生
- 药物治疗 药物治疗
背景情况:
- 对中度至重度的牛皮有系统治疗的指示,但丹麦的全国治疗率没有得到充分记录.
- 了解治疗模式对于优化患者护理和资源配置至关重要.
研究的目的:
- 确定在丹麦中度至重度牛皮患者中使用常规系统治疗的流行率.
- 调查常规系统治疗的持续时间,以及在以前没有生物治疗的患者中启动生物治疗的时间.
主要方法:
- 一项基于登记册的研究,利用丹麦国家数据来识别牛皮患者队列.
- 使用注册表数据估计了中度至重度牛皮的患病率,并应用了反向概率权重来解决潜在的选择偏差.
- 对加权队列进行了分析,以评估治疗模式和时间表.
主要成果:
- 据估计,大约10.9%的丹麦牛皮患者患有中度至重度的疾病.
- 其中37.7%的人尽管是候选人,但没有接受任何全身治疗.
- 传统系统性治疗的治疗持续时间缩短了 (2014-2018年平均为0.6年,而1985-1994年为3.0年),生物启动的时间显著减少.
结论:
- 丹麦中度至重度牛皮病患者中,很大一部分仍未得到全身疗法治疗.
- 传统系统性治疗的药物存活率下降,表明需要重新评估治疗策略.
- 向更早的生物启动的转变表明严重牛皮的治疗范式正在演变.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Psychosis: Goals of Pharmacotherapy
165
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
165
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
150
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
150
Drug Therapy
68
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
68


